Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Atossa Genetics, Inc. to Contact the Firm

ATOS

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Atossa Genetics, Inc. to Contact the Firm

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Atossa Genetics, Inc. to Contact the Firm

NEW YORK, NY--(Marketwired - Nov 15, 2013) -  Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Atossa Genetics, Inc. ("Atossa" or the "Company") (NASDAQ: ATOS) of the December 9, 2013 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Atossa and certain executives.

A complaint has been filed on behalf of all persons who purchased or otherwise acquired Atossa shares between November 8, 2012 and October 4, 2013 (the "Class Period") in the Western District of Washington.

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that throughout the Class Period Atossa issued false and/or misleading statements regarding the Company's improperly marketing of its devices utilizing certain promotional claims concerning the ForeCYTE Breast Health Test and the MASCT device.

On October 4, 2013, Atossa announced that it was initiating a recall to remove the ForeCYTE Breast Health Test and the MASCT device from the market due to concerns of the FDA communicated in a warning letter.

Following this news, the Company's stock declined $2.47 per share, or over 46%, to close at $2.85 per share on October 7, 2013.

Request more information now by clicking here: www.faruqilaw.com/ATOS. There is no cost or obligation to you.

Take Action

If you invested in Atossa stock or options between November 8, 2012 and October 4, 2013 and would like to discuss your legal rights, visit www.faruqilaw.com/ATOS. You can also contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Atossa's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

FARUQI & FARUQI, LLP
369 Lexington Avenue, 10th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
Email Contact
Francis McConville, Esq.
Email Contact
Telephone: (877) 247-4292 or (212) 983-9330



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today